CERENO SCIENTIFIC AB B (4A1) - Total Liabilities
Based on the latest financial reports, CERENO SCIENTIFIC AB B (4A1) has total liabilities worth €150.20 Million EUR (≈ $175.60 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 4A1 shareholders equity momentum to track the company's year-over-year net asset growth rate.
CERENO SCIENTIFIC AB B - Total Liabilities Trend (2021–2025)
This chart illustrates how CERENO SCIENTIFIC AB B's total liabilities have evolved over time, based on quarterly financial data.
CERENO SCIENTIFIC AB B Competitors by Total Liabilities
The table below lists competitors of CERENO SCIENTIFIC AB B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
i-SENS Inc
KQ:099190
|
Korea | ₩234.55 Billion |
|
IG Petrochemicals Limited
NSE:IGPL
|
India | Rs9.68 Billion |
|
Sula Vineyards Limited
NSE:SULA
|
India | Rs5.08 Billion |
|
Braemar Hotel & Resorts Inc
NYSE:BHR
|
USA | $1.35 Billion |
|
Getty Images Holdings Inc.
NYSE:GETY
|
USA | $2.63 Billion |
|
Sanara Medtech Inc
NASDAQ:SMTI
|
USA | $67.01 Million |
|
Westwood Holdings Group Inc
NYSE:WHG
|
USA | $24.31 Million |
|
Petronor E&P Ltd
OL:PNOR
|
Norway | Nkr51.78 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down CERENO SCIENTIFIC AB B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of CERENO SCIENTIFIC AB B.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CERENO SCIENTIFIC AB B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CERENO SCIENTIFIC AB B (2021–2025)
The table below shows the annual total liabilities of CERENO SCIENTIFIC AB B from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €150.20 Million ≈ $175.60 Million |
-32.29% |
| 2024-12-31 | €221.85 Million ≈ $259.36 Million |
+223.57% |
| 2023-12-31 | €68.56 Million ≈ $80.16 Million |
+384.80% |
| 2022-12-31 | €14.14 Million ≈ $16.53 Million |
+32.50% |
| 2021-12-31 | €10.67 Million ≈ $12.48 Million |
-- |
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an … Read more